Pasireotide‐induced hyperglycemia in a patient with Cushing's disease: Potential use of sodium‐glucose cotransporter 2 inhibitor and glucagon‐like peptide‐1 receptor agonist for treatment. Issue 12 (13th August 2020)

• Record Type: Journal Article
• Authors: Shikata, Masato; Ashida, Kenji; Goto, Yuka; Nagayama, Ayako; Iwata, Shimpei; Yano, Mamiko; Hasuzawa, Nao; Hara, Kento; Mawatari, Kazutoshi; Sakata, Kiyohiko; Tsuruta, Munehisa; Wada, Nobuhiko; Nomura, Masatoshi
• Is Part Of: Clinical case reports. Volume 8:Issue 12(2020)
• Page Start: 2613
• Page End: 2618
• Publication Date: 2020-08-13
• Subjects: Cushing's disease -- diabetes mellitus -- glucagon‐like peptide‐1 receptor agonist -- pasireotide -- sodium‐glucose cotransporter 2 inhibitor; Medicine -- Periodicals; 616.09
• DOI: 10.1002/ccr3.3230
• Languages: English
• ISSNs: 2050-0904

Abstract

Abstract: Pasireotide improves hypercortisolemia and induces hyperglycemia via somatostatin receptor type‐5 stimulation. GLP‐1RA and SGLT2 inhibitor potentially help regulate hyperglycemia in patients with Cushing's disease, especially after pasireotide administration. Abstract : Pasireotide improves hypercortisolemia and induces hyperglycemia via somatostatin receptor type‐5 stimulation. GLP‐1RA and SGLT2 inhibitor potentially help regulate hyperglycemia in patients with Cushing's disease, especially after pasireotide administration.